Ann: Company Update on COVID-19, page-22

These two slides provide a good summary of yesterday CSL investor webcast briefing:






Some key point mentioned by the CSL Exec team during the briefing:

• CSL is processing the plasma collected last year this year and that is why their forecasts remain in track
• Current blood collection challenges will impact next years results, however, they have some mitigation strategies that they follow to attempt to address the impact.
• It was mentioned that they have to hold plasma for 60 days before they can start to use it. They mentioned they are talking to the FDA in USA to see if they can have this period reduced ... 45 days was mentioned.
• When CSL spoke about their focus on COVID-19 Response (Refer to 2nd slide above), they made the following comments:
• The Aus Gov created CSL 100 years ago and set up a pandemic response capability. CSL today still has and still uses many of the capabilities they initially established way back then. They are proud about their heritage and their company's values and culture.
• This was an important point for me - it was mentioned that CSL is quite unique in the breadth and depth of its IP, capabilities and collaboration partnerships it has - no other company has all this breadth and depths. The CEO made a comment something like this (words may not be exact) .... if you were going to design and create a new exciting Bio company today, then the capabilities you see on the slide (2nd slide above) would be a perfect profile ... something like that.

I will be watching with interest on how their collaboration with SAB Bio on several fronts, CONVID and IG, evolves over the coming months.

Great company. Good luck to all investors.